EUVIMEDEUVIMED entdecken
Open Access

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Paul Bastard iD, Sara E Vazquez iD, Jamin Liu iD, Matthew T Laurie iD, Chung Yu Wang, Adrian Gervais iD, Tom Le Voyer iD, Lucy Bizien iD, Colin Zamecnik iD, Quentin Philippot, Jérémie Rosain iD, Emilie Catherinot und 48 weitere

Science Immunology · 22.12.2023 · 8 (90)

DOI: 10.1126/sciimmunol.abp8966 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 22.12.2023. Verfasst von Paul Bastard und 59 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France. Hauptthemen laut MEDLINE: COVID-19, Vaccines, Interferon Type I. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCRR NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VaccinesInterferon Type IHumansCOVID-19 VaccinesSARS-CoV-2VaccinationRNA, Messenger

Substanzen

COVID-19 VaccinesVaccinesInterferon Type IRNA, Messenger

Autor:innen und Institutionen

  • Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Imagine Institute, University of Paris Cité, Paris, France.
  • St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.
  • Department of Pediatrics, Necker Hospital for Sick Children, AP-HP, Paris, France.
  • Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Tetrad Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA.

ORCID-Profile: Paul Bastard, Sara E Vazquez, Jamin Liu, Matthew T Laurie, Adrian Gervais, Tom Le Voyer, Lucy Bizien, Colin Zamecnik, Jérémie Rosain, Arnaud Fekkar, Garyphallia Poulakou, Eleni Siouti, Günter Weiss, Jérémy Manry, Sotirija Duvlis, Daniel Arroyo-Sánchez, Cristiano Perani, Alessandra Sottini, Virginia Quaresima, Lucie Roussel, Donald C Vinh, Luis Felipe Reyes, Nevin Hatipoglu, David Boutboul, Alessandro Borghesi, Anna Aliberti, Irene Cassaniti, Fabienne Venet, Guillaume Monneret, Rabih Halwani, Narjes Saheb Sharif-Askari, Jeffrey Danielson, Sonia Burrel, Caroline Morbieu, Yurii Stepanovskyy, Alla Volokha, Oksana Boyarchuk, Alenka Gagro, Mathilde Neuville

Förderung

  • NCATS NIH HHS
  • NCRR NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS

Zitieren

APA

Bastard, P., Vazquez, S. E., Liu, J., Laurie, M. T., Wang, C. Y., Gervais, A., Le Voyer, T., Bizien, L., Zamecnik, C., Philippot, Q., Rosain, J., Catherinot, E., Willmore, A., Mitchell, A. M., Bair, R., Garçon, P., Kenney, H., Fekkar, A., Salagianni, M., …, & Hernu, R. (2023). Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 8(90). https://doi.org/10.1126/sciimmunol.abp8966

Vancouver

Bastard P, Vazquez SE, Liu J, Laurie MT, Wang CY, Gervais A, et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology. 2023;8(90). doi:10.1126/sciimmunol.abp8966

BibTeX
@article{Bastard2023,
  author = {Bastard, Paul and Vazquez, Sara E and Liu, Jamin and Laurie, Matthew T and Wang, Chung Yu and Gervais, Adrian and Le Voyer, Tom and Bizien, Lucy and Zamecnik, Colin and Philippot, Quentin and Rosain, Jérémie and Catherinot, Emilie and Willmore, Andrew and Mitchell, Anthea M and Bair, Rebecca and Garçon, Pierre and Kenney, Heather and Fekkar, Arnaud and Salagianni, Maria and Poulakou, Garyphallia and Siouti, Eleni and Sahanic, Sabina and Tancevski, Ivan and Weiss, Günter and Nagl, Laurenz and Manry, Jérémy and Duvlis, Sotirija and Arroyo-Sánchez, Daniel and Paz Artal, Estela and Rubio, Luis and Perani, Cristiano and Bezzi, Michela and Sottini, Alessandra and Quaresima, Virginia and Roussel, Lucie and Vinh, Donald C and Reyes, Luis Felipe and Garzaro, Margaux and Hatipoglu, Nevin and Boutboul, David and Tandjaoui-Lambiotte, Yacine and Borghesi, Alessandro and Aliberti, Anna and Cassaniti, Irene and Venet, Fabienne and Monneret, Guillaume and Halwani, Rabih and Sharif-Askari, Narjes Saheb and Danielson, Jeffrey and Burrel, Sonia and Morbieu, Caroline and Stepanovskyy, Yurii and Bondarenko, Anastasia and Volokha, Alla and Boyarchuk, Oksana and Gagro, Alenka and Neuville, Mathilde and Neven, Bénédicte and Keles, Sevgi and Hernu, Romain},
  title = {Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs},
  journal = {Science Immunology},
  year = {2023},
  volume = {8},
  number = {90},
  doi = {10.1126/sciimmunol.abp8966}
}
Kostenlos starten →